Drug: Skyrizi (risankizumab)

Manufacturer: AbbVie

Route of Administration: Intravenous, Subcutaneous

Site of Care: Outpatient

Approved Indication:

• treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
• treatment of active psoriatic arthritis in adults
• treatment of moderately-to-severely active Crohn’s disease in adults
• treatment of moderately-to-severely active ulcerative colitis in adults

Disease: Crohn’s disease, plaque psoriasis, psoriatic arthritis, ulcerative colitis

Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

Enrollment Form Link: Skyrizi Complete

Phone Number: 1-866-759-7494

Fax Number: 1-678-727-0690

Product Website: skyrizi.com